Pre header text goes here. Will show on inbox
To view this email as a web page, click here.

 
ADVERTISEMENT
Sernivo
 
Industry updates
 
Allergan to acquire Zeltiq
The multi-billion dollar deal is expected to close in the second half of 2017.
Read more about this acquisition
 
ADVERTISEMENT
 
 
 
NO drug falters in study
Derms weigh in on the future of nitric oxide drugs for acne treatment.
Learn more about the implications
 
In case you missed it
 
What should dermatologists do when a merger beckons?
Data breaches: Fast facts
Coding 2017 and beyond
 
DIGITAL EDITION
February Features
Keloid care, MCC treatment, EHR liability and more are all inside this month's issue of Dermatology Times.
Catch up on today's trends
JOB OPPORTUNITIES
 
 
 
ADVERTISEMENT
A patented, novel formulation, delivering versatility
Introducing Sernivo™ (betamethasone dipropionate) Spray, 0.05%, featuring a new, innovative oil-in-water emulsion. Learn More about this elegant formulation, delivered as a spray.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.